[HTML][HTML] Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelson, N Donin, S Zell, S Schultz… - Molecular immunology, 2003 - Elsevier
Monoclonal antibodies (mAbs) are being increasingly used in cancer therapy owing to their
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelson, N Donin, S Zell, S Schultz… - Molecular …, 2003 - pubmed.ncbi.nlm.nih.gov
Monoclonal antibodies (mAbs) are being increasingly used in cancer therapy owing to their
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
[PDF][PDF] Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelsona, N Donina, S Zellb, S Schultzb… - Molecular …, 2003 - academia.edu
Monoclonal antibodies (mAbs) are being increasingly used in cancer therapy owing to their
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
[引用][C] Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelson - Molecular Immunology, 2003 - cir.nii.ac.jp
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins
(mCRPs) in tumors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
(mCRPs) in tumors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelson, N Donin, S Zell, S Schultz… - Molecular Immunology, 2003 - infona.pl
Monoclonal antibodies (mAbs) are being increasingly used in cancer therapy owing to their
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
Z Fishelson, N Donin, S Zell, S Schultz… - Molecular …, 2003 - europepmc.org
Monoclonal antibodies (mAbs) are being increasingly used in cancer therapy owing to their
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …
[引用][C] Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z FISHELSON - Mol Immunol, 2003 - cir.nii.ac.jp
Obstacles to cancer immunotherapy : expression of membrane complement regulatory proteins
(mCRPs) in tumors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
(mCRPs) in tumors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …